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Abstract. 
Hepatic sarcomatoid carcinoma is a rare malignant neoplasm composed of both carcino-
matous and sarcomatous components. It has a higher risk of relapse and distant metastasis 
compared with ordinary hepatocellular carcinoma despite of radical resection. To date, there is 
no effective treatment available for patients with metastatic hepatic sarcomatoid carcinoma, and 
their prognosis is extremely poor. We present a case of hepatic sarcomatoid carcinoma relapsing 
after surgical resection in which complete remission was achieved by chemotherapy. This 68 
year-old female patient was diagnosed with a 5.7 cm liver tumor with partial portal vein 
thrombosis. She underwent right hepatic lobectomy and cholecystectomy. Pathology revealed 
hepatic sarcomatoid carcinoma with venous invasion. Multiple recurrent intrahepatic tumors 
and lymphadenopathies were found by CT scan 3 months after surgical resection. She received 
salvage chemotherapy consisting of seven cycles of doxorubicin and ifosfamide and achieved 
complete remission. She has remained disease free. 
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病例報告  
復發性肝臟類肉瘤上皮癌經化學治療治癒 
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中文摘要 
    肝臟類肉瘤上皮癌是同時含有上皮癌和肉瘤兩種組成成分的一種罕見惡性腫瘤。與
一般的肝細胞癌相比，這種腫瘤在根治性切除手術後有較高的復發和遠端轉移的風險。
此外，目前對於患有轉移性肝臟類肉瘤上皮癌的患者並沒有有效的治療，因此預後很差。
在此我們提出一位患有肝臟類肉瘤上皮癌的個案，雖然在手術後復發並合併淋巴轉移，
但在化學治療後達到完全緩解。這位 68 歲女性被診斷有一個 5.7 公分肝腫瘤合併有肝門
靜脈部分栓塞而接受肝右葉切除及膽囊切除。病理報告顯示肝臟類肉瘤上皮癌合併靜脈
侵犯。手術後三個月的電腦斷層發現多顆肝內復發腫瘤。她隨後接受 7 個療程的
doxorubicin 合併 ifosfamide 化學治療而達到完全緩解並在那之後維持無病狀態。 
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INTRODUCTION 
Hepatic sarcomatoid carcinoma is a rare malignant 
neoplasm of the liver with an incidence of only about 
1.8-2% of surgically resected hepatic tumors and 
3.9-9.4% of autopsy cases [1-3]. Sarcomatoid carci-
noma is composed of both carcinomatous and sarco-
matous components. The sarcomatous component 
within sarcomatoid carcinoma is actually very poorly 
differentiated carcinoma with morphological features 
of sarcoma, such as spindle shape cells, rather than a 
true sarcoma. Besides, the sarcomatous component of 
sarcomatoid carcinoma also expresses epithelial mark-
ers immunohistochemically[4-6]. Sarcomatoid car-
cinoma behaves more aggressively clinically and has 
worse prognosis than ordinary hepatocellular carci-
noma because of its frequent metastasis, low resecta-
bility rate, and high recurrence rate [1,2]. For patients 
with surgically unresectable disease, there is no effec-
tive or standardized treatment, and their prognosis is 
extremely poor. We hereby describe a patient with 
recurrent hepatic sarcomatoid carcinoma after surgical 
resection. She achieved complete remission after re-
ceiving salvage chemotherapy and has remained dis-
ease free for 8 months. 
 
CASE REPORT 
A 68-year-old lady experienced decreased appetite, 
right upper abdominal pain, and weight loss for one 
month and was referred to our hospital as abdominal 
ultrasonography performed at a local hospital showed 
a 5 cm tumor at S8 of the liver. Laboratory data re-
vealed normal serum levels of total bilirubin (0.59 
mg/dl; normal 0.20-1.20 mg/dl), aspartate ami-
notransferase (14 U/l; normal 0-31 U/l), alanine ami- 
 
 
 
 
 
 
 
 
 
 
Figure 1. Abdominal CT at diagnosis showed periph-
eral enhancement on arterial phase 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Abdominal CT at diagnosis showed washout 
on venous phase 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Abdominal MRI at diagnosis revealed rim 
enhancement in hepatic arterial phase 
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Figure 4. Abdominal MRI at diagnosis disclosed par-
tial thrombosis (arrow) of branches of por-
tal vein at S8 
 
 
notransferase (9 U/l; normal 0-31 U/l), alkaline phos-
phatase (71 U/l; normal 34-104 U/l), r-glutamyl 
transpeptidase (22U/l; normal 9-64 U/l), and alpha 
fetoprotein (3.99 ng/ml; normal 0-20 ng/ml). The se-
rology tests were negative for HBsAg and positive for 
anti-HBs and anti-HCV Ab. Abdominal triphasic CT 
scan disclosed a 5.6 cm hypodense tumor at the dome 
of S8 of the liver with peripheral enhancement on ar-
terial phase and washout on venous phase and a 0.9 
cm hypodense lesion at the pancreatic tail (Figure 1,2). 
Abdominal MRI showed a 5.7 cm tumor at high S8 of 
the liver with partial thrombosis of branches of the 
portal vein at S8, a 0.7 cm cystic lesion at the pancre-
atic tail, and splenomegaly. The tumor had mild rim 
enhancement in the hepatic arterial phase with denser 
and thicker marginal enhancement in delayed phase 
(Figure 3,4). Under the impression of cholangiocarci-
noma, she underwent right hepatic lobectomy. A huge, 
firm, yellowish tumor about 7x7x4 cm in size at S7/8 
with diaphragm invasion, mild liver cirrhosis, and 
some yellowish ascites were found intraoperatively.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Microscopic examination of the sarcoma-
toid carcinoma revealed a malignant epi-
thelioid and spindle cell tumor with infil-
trating borders in an inflamed stroma 
(H&E x100) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The tumor was composed of non-adhesive 
spindle shaped or fusiform cells with oval 
to round pleomorphic nuclei, prominent 
nucleoli and frequent mitosis (H&E x400) 
 
 
The involved diaphragm was resected. Pathology re-
vealed a malignant epithelioid and spindle cell tumor 
with infiltrating border in an inflamed stroma. No 
typical carcinoma component was present in the 
specimen (Figure 5,6). There were focal vascular ec-
tasia in close relation to the tumor cells. Perforation of 
the visceral peritoneum with diaphragm invasion was  
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Figure 7. Immunohistochemical staining for cy-
tokeratin (AE1/AE3) was focally positive 
(x100) 
Figure 8. The tumor cells were positive for vimentin 
(x200) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The tumor cells were negative for hep-par-1 
(x100) 
Figure 10. The tumor cells were negative for arginase 
1 (x100) 
 
 
observed. Immunohistochemically, the tumor was 
positive for cytokeratin (AE1/AE3) and vimentin, but 
negative for CD31, Arginase 1, hep-par-1, S-100, and 
Desmin (Figure 7-12). Grade 4 sarcomatoid carcino-
ma, T4N0M0, stage IIIc, with closed surgical margin 
was diagnosed. She had an uneventful post-operative 
recovery and was discharged 10 days later. She was 
regularly followed-up at general surgery outpatient 
department. 
The patient still experienced fatigue, anorexia, 
weight loss, and right upper quadrant pain after the 
operation. Three months later, several hypoechoic 
nodules in both hepatic lobes were found by ab-
dominal sonography. The largest one was 2.7 cm in 
diameter. Chest to pelvic CT scan revealed multiple 
recurrent hypervascular tumors at both lobes of the 
liver and lymphadenopathy at the hepatic hilum, 
paraaortic region, mediastinum, and left internal 
mammary chain (Figure 13). Salvage chemotherapy 
with doxorubicin and ifosfamide [doxorubicin 50 
mg/m2 infusion for 10 minutes on day 1 and 
ifosfamide 2000 mg/m2 infusion for 4 hours on days 1 
and 2] was administrated in 5 cycles. Complete remis-
sion, which was confirmed by CT scan after the fifth  
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Figure 11. The tumor cells are negative for S-100 
stain (x200) 
Figure 12. The tumor cells were negative for desmin 
(x100) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Abdominal CT showed recurrent hyper-
vascular tumors (broad arrow heads) with 
paraaortic lymphadenopathy (arrows) 
Figure 14. CT scan follow-up after chemotherapy 
showed no residual tumor (broad arrow 
heads and arrows) 
 
 
cycle of chemotherapy, was reached. She received two 
more cycles of chemotherapy with doxorubicin and 
ifosfamide. She has remained disease free for more 
than 8 months after the last cycle of chemotherapy 
(Figure 14). 
 
 
DISCUSSION 
Hepatic sarcomatoid carcinoma is a rare neoplasm 
of the liver with and aggressive clinical course and 
dismal prognosis regardless of treatment [3]. The tu-
mor cells exhibit infiltrative growth pattern and high 
frequency of widespread metastasis. The median sur-
vival times range from 9.6 to 11.5 months, and the 
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3-year survival rate ranges from 14.3% to 18.2% 
[7-9]. Even liver transplantation, patients have a 
3-year survival rate of only 37.5%, and the disease 
will relapse in as high as 75% of patients [9]. Early 
detection and radical resection of the tumor may pro-
vide the best chance of cure. 
In patients who suffer from recurrence after surgi-
cal resection, no treatments have been proven effec-
tive. Patients treated as ordinary hepatocellular carci-
noma with re-excision, transarterial chemoemboliza-
tion, radiofrequency ablation, percutaneous micro-
wave ablation, and radiation therapy, usually have 
poor outcome due to their limited therapeutic effect 
[7-9]. To date, the effect of chemotherapy on sarco-
matoid carcinoma of liver remains uncertain. There 
are case reports of successful treatment of metastatic 
sarcomatoid carcinoma of bladder with adriblastine 
plus ifosfamide and successful treatment of metastatic 
sarcomatoid renal cell carcinoma with gemcitabine 
and doxorubicin [10,11]. However, pulmonary sarco-
matoid carcinoma has a high rate of resistance to 
chemotherapy [12]. In the present case, the combina-
tion of doxorubicin and ifosfamide, the commonly 
used regimen for first-line therapy of pure sarcoma-
tous mesenchymal neoplasm, had an excellent effect. 
The present case suggests that hepatic sarcomatoid 
carcinoma may be more sensitive to chemotherapy 
than ordinary hepatocellular carcinoma. 
The pathogenesis of sarcomatoid carcinoma is still 
not fully understood. The sarcomatoid component is 
thought to be derived from de-differentiation and 
transformation of the carcinomatous component, ra-
ther than a mixture of carcinoma and sarcoma [1-3,9, 
13-17]. Hepatocellular carcinoma is well known for its 
high resistance to chemotherapy. The tumor cells in 
hepatic sarcomatoid carcinoma may change their 
properties, including the sensitivity to chemotherapy 
during the transformation process. This case suggests 
that chemotherapy with doxorubicin and ifosfamide 
can be a viable therapeutic option for hepatic sarco-
matoid carcinoma. 
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